Nanotechnology approaches to addressing HER2-positive breast cancer

Cancer Nanotechnology

Molly K. White¹  Alexandru S. Biris¹  Zeid A. Nima¹  Het Adhvaryu²  Nawab Ali²  Bryan E. White²  Issam Makhoul³ 

[1]Center for Integrative Nanotechnology Sciences, University of Arkansas at Little Rock

[2]Department of Biology, College of Arts, Letters and Sciences, University of Arkansas at Little Rock

[3]Medical Oncology, University of Arkansas for Medical Sciences

关键词: HER2;    Breast cancer;    Nanotechnology;    Targeting;    Cellular uptake;    Screening;   

DOI  :  10.1186/s12645-020-00068-2

来源: DOAJ

【 摘 要 】

Abstract Breast cancer is a major cause of cancer-associated deaths in the United States. It was estimated that 12% of women in the U.S. will develop invasive breast cancer in their lifetime. The human epidermal growth factor receptor (HER2/neu) is a growth-promoting protein that is overexpressed in 15–20% of breast cancers (HER2-positive breast cancer). HER2-positive breast cancer generally grows and spreads more quickly than other breast cancers, but it can be targeted therapeutically. Targeting drugs have been developed with a specific design to stop the growth and even the spread of cancer. These drugs include trastuzumab (Herceptin), pertuzumab (Perjeta), ado-trastuzumab emtansine (Kadcyla, or TDM-1), fam-trastuzumab deruxtecan, lapatinib, neratinib and tucatinib. However, the need for better targeted therapy and efficacy still exists. Nanotechnology could have major advantages in terms of detection, targeting, drug delivery, and destruction of cancer cells and tumors. Although a great deal of progress has been accomplished major challenges still need to be addressed. In this review, we examine the major areas of research in the area of nanotechnology and HER2-positive breast cancer.

【 授权许可】

Unknown